BioMarin Pharmaceutical Inc. – NASDAQ:BMRN
BioMarin Pharmaceutical stock price today
$57
-9.89
-14.79%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
BioMarin Pharmaceutical stock price monthly change
-21.32%
month
BioMarin Pharmaceutical stock price quarterly change
-21.32%
quarter
BioMarin Pharmaceutical stock price yearly change
-31.66%
year
BioMarin Pharmaceutical key metrics
Market Cap | 12.45B |
Enterprise value | 18.56B |
P/E | 132.22 |
EV/Sales | 8.85 |
EV/EBITDA | 69.57 |
Price/Sales | 8.68 |
Price/Book | 3.95 |
PEG ratio | 0.41 |
EPS | 1.08 |
Revenue | 2.47B |
EBITDA | 280.99M |
Income | 205.45M |
Revenue Q/Q | 9.42% |
Revenue Y/Y | 14.10% |
Profit margin | 6.75% |
Oper. margin | 1.99% |
Gross margin | 76.92% |
EBIT margin | 1.99% |
EBITDA margin | 11.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioMarin Pharmaceutical stock price history
BioMarin Pharmaceutical stock forecast
BioMarin Pharmaceutical financial statements
Average Price Target
$97.16
Potential upside: 70.45%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 594.59M | 56.04M | 9.42% |
|---|---|---|---|
| Sep 2023 | 585.96M | 40.37M | 6.89% |
| Dec 2023 | 646.20M | 20.37M | 3.15% |
| Mar 2024 | 648.83M | 88.66M | 13.66% |
| 2023-04-26 | 0.18 | 0.27 |
|---|
| Jun 2023 | 6563172000 | 1.78B | 27.13% |
|---|---|---|---|
| Sep 2023 | 6758163000 | 1.86B | 27.54% |
| Dec 2023 | 6841603000 | 1.89B | 27.63% |
| Mar 2024 | 6872673000 | 1.79B | 26.17% |
| Jun 2023 | 70.06M | 29.53M | 11.96M |
|---|---|---|---|
| Sep 2023 | 135.64M | -45.79M | -788K |
| Dec 2023 | 27.48M | -64.96M | 10.84M |
| Mar 2024 | 46.97M | -14.23M | -42.79M |
BioMarin Pharmaceutical alternative data
| Sep 2023 | 3,082 |
|---|---|
| Oct 2023 | 3,082 |
| Nov 2023 | 3,082 |
| Dec 2023 | 3,082 |
| Jan 2024 | 3,082 |
| Feb 2024 | 3,082 |
| Mar 2024 | 3,401 |
| Apr 2024 | 3,401 |
| May 2024 | 3,401 |
| Jun 2024 | 3,401 |
| Jul 2024 | 3,401 |
BioMarin Pharmaceutical other data
95.20%
-0.97%
of BMRN is owned by hedge funds
531
-2
174.07M
-2.11M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 23764 |
| Jan 2024 | 0 | 20000 |
| Feb 2024 | 0 | 31000 |
| Mar 2024 | 0 | 65943 |
| Apr 2024 | 0 | 42286 |
| May 2024 | 0 | 92700 |
| Aug 2024 | 0 | 714 |
| Nov 2024 | 0 | 5278 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GUYER CHARLES GREG officer: EVP, Chief Technical O.. | Common Stock | 5,278 | $66.37 | $350,322 | ||
Sale | BURKHART ERIN officer: GVP, Chief Accounting .. | Common Stock | 714 | $90 | $64,260 | ||
Option | HERON ELAINE J director | Common Stock | 5,047 | $63.1 | $318,466 | ||
Option | HERON ELAINE J director | Stock Option (Right to Buy Common Stock) | 5,047 | $63.1 | $318,466 | ||
Option | MEIER RICHARD A director | Common Stock | 6,600 | $63.1 | $416,460 | ||
Option | MEIER RICHARD A director | Stock Option (Right to Buy Common Stock) | 6,600 | $63.1 | $416,460 | ||
Option | MUELLER BRIAN officer: EVP, Chi.. | Stock Option (Right to Buy Common Stock) | 5,000 | $63.1 | $315,500 | ||
Option | MUELLER BRIAN officer: EVP, Chi.. | Common Stock | 5,000 | $63.1 | $315,500 | ||
Sale | MUELLER BRIAN officer: EVP, Chi.. | Common Stock | 5,000 | $75.19 | $375,950 | ||
Option | DAVIS GEORGE ERIC officer: EVP, Chi.. | Common Stock | 40,850 | $63.1 | $2,577,635 |
| Quarter | Transcript |
|---|---|
| Q1 2024 24 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 31 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Jean-Jacques Bienaime M.B.A., MBA (1953) Chairman & Chief Executive Officer | $3,060,000 |
| Dr. Henry J. Fuchs (1958) Pres of Worldwide R&D | $1,340,000 |
Dr. C. Greg Guyer Ph.D. (1962) Chief Technology Officer and Executive Vice President of Global Manufacturing & Technical Operations | $1,070,000 |
| Mr. Jeffrey Robert Ajer (1962) Executive Vice President & Chief Commercial Officer | $1,050,000 |
| Mr. Brian R. Mueller (1974) Executive Vice President of Fin. & Chief Financial Officer | $985,510 |
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
An Update On Ascendis Pharma's Path To Profitability
BioMarin: Growth Drivers Remain Intact
BioMarin: Q2 2023 Confirmed My Bullish View
Rare Buy Picks In July 2023 - From 29 Discerning Analysts
BioMarin: More Growth Is Coming
BioMarin: FDA Approval Of ROCTAVIAN And Massive VOXZOGO Sales Increase
BioMarin: Decision Day For Hemophilia Gene Therapy Upcoming - Approval Likely
BridgeBio Pharma: A Lot Of Paths To Potential Success
-
What's the price of BioMarin Pharmaceutical stock today?
One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $57.
-
When is BioMarin Pharmaceutical's next earnings date?
Unfortunately, BioMarin Pharmaceutical's (BMRN) next earnings date is currently unknown.
-
Does BioMarin Pharmaceutical pay dividends?
No, BioMarin Pharmaceutical does not pay dividends.
-
How much money does BioMarin Pharmaceutical make?
BioMarin Pharmaceutical has a market capitalization of 12.45B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15.42% to 2.42B US dollars. BioMarin Pharmaceutical earned 167.65M US dollars in net income (profit) last year or $0.27 on an earnings per share basis.
-
What is BioMarin Pharmaceutical's stock symbol?
BioMarin Pharmaceutical Inc. is traded on the NASDAQ under the ticker symbol "BMRN".
-
What is BioMarin Pharmaceutical's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioMarin Pharmaceutical?
Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the following people:
- Mr. Jean-Jacques Bienaime M.B.A., MBA Chairman & Chief Executive Officer(age: 72, pay: $3,060,000)
- Dr. Henry J. Fuchs Pres of Worldwide R&D(age: 67, pay: $1,340,000)
- Dr. C. Greg Guyer Ph.D. Chief Technology Officer and Executive Vice President of Global Manufacturing & Technical Operations(age: 63, pay: $1,070,000)
- Mr. Jeffrey Robert Ajer Executive Vice President & Chief Commercial Officer(age: 63, pay: $1,050,000)
- Mr. Brian R. Mueller Executive Vice President of Fin. & Chief Financial Officer(age: 51, pay: $985,510)
-
How many employees does BioMarin Pharmaceutical have?
As Jul 2024, BioMarin Pharmaceutical employs 3,401 workers.
-
When BioMarin Pharmaceutical went public?
BioMarin Pharmaceutical Inc. is publicly traded company for more then 26 years since IPO on 26 Jul 1999.
-
What is BioMarin Pharmaceutical's official website?
The official website for BioMarin Pharmaceutical is biomarin.com.
-
Where are BioMarin Pharmaceutical's headquarters?
BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael, CA.
-
How can i contact BioMarin Pharmaceutical?
BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael, CA and company can be reached via phone at +41 55066700.
-
What is BioMarin Pharmaceutical stock forecast & price target?
Based on 14 Wall Street analysts` predicted price targets for BioMarin Pharmaceutical in the last 12 months, the avarage price target is $97.16. The average price target represents a 70.45% change from the last price of $57.
BioMarin Pharmaceutical company profile:
BioMarin Pharmaceutical Inc.
biomarin.comExchange:
NASDAQ
Full time employees:
3,401
Industry:
Biotechnology
Sector:
Healthcare
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
770 Lindaro Street
San Rafael, CA 94901
San Rafael, CA 94901
CIK: 0001048477
ISIN: US09061G1013
CUSIP: 09061G101
